Evidence map›Paper›PMID 33574085›Full record

ArticleCancer research2021

Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.

Tengjiao Ma, Chengchen Hu, Bachchu Lal, Weiqiang Zhou, Yongxin Ma, Mingyao Ying, Panagiotis Prinos, Alfredo Quiñones-Hinojosa, Michael Lim, John Laterra and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 59 citations in OpenAlex.

  1. Nerve growth factor receptor (NGFR): A key player in glioblastoma progression.Biochimica et biophysica acta. Reviews on cancer · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Tengjiao Ma *Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.ORCID 0000-0002-0848-9117
Chengchen Hu *Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.ORCID 0000-0002-9957-9256
Bachchu LalHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.
Weiqiang ZhouDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Yongxin MaDepartment of Medical Genetics, State Key Laboratory of Biotherapy, West China Hospital and Collaborative Innovation Center, Sichuan University, Chengdu, China.
Mingyao YingHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.
Panagiotis PrinosStructural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-8785-7856
Alfredo Quiñones-HinojosaDepartment of Neurosurgery and Oncology, Mayo Clinic, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Michael LimDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
John LaterraHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland. laterra@kennedykrieger.org liyu@kennedykrieger.org.
Yunqing LiHugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland. laterra@kennedykrieger.org liyu@kennedykrieger.org.
Kennedy Krieger Institute · USJohns Hopkins University · USSichuan University · CNStructural Genomics Consortium · CA

Funding

Intra-Operative, Label-Free Detection of Brain Cancer Infiltration with Quantitative Optical ImagingR01CA200399 · NCI · JOHNS HOPKINS UNIVERSITY · PI LI, XINGDE, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$3.0M
A novel microfluidic device to predict brain cancer prognosis and response to therapyR01CA216855 · NCI · MAYO CLINIC JACKSONVILLE · PI KONSTANTOPOULOS, KONSTANTINOS, QUINONES-HINOJOSA, ALFREDO · 2018 to 2022
$2.4M
Chromatin Modifications in GBM-Propagating CellsR01NS096754 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2017 to 2021
$2.2M
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)R01CA195503 · NCI · MAYO CLINIC JACKSONVILLE · PI GREEN, JORDAN, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$1.9M
Targeting Hyaluronan-mediated Motility Receptor in Glioblastoma Stem CellsR01NS099460 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI YING, MINGYAO · 2017 to 2021
$1.8M
Tet2 regulation and function in glioma cell phenotype reprogrammingR01NS110087 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2019 to 2023
$1.8M
Brain Cancer Stem Cell Reprogramming by c-MetR01NS073611 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2012 to 2016
$1.8M
Paracrine Angiotensin II Signaling Promotes Medulloblastoma through MYC ActivationR21NS101400 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI YING, MINGYAO · 2018 to 2019
$445k
Targeting TAZ-driven oncogenic signaling in MedulloblastomaR21NS106407 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI YING, MINGYAO · 2018 to 2019
$445k
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapyR43CA221490 · NCI · CELL REPROGRAMMING AND THERAPEUTICS, LLC · PI ALEXANIAN, ARSHAK R, QUINONES-HINOJOSA, ALFREDO · 2018 to 2018
$300k
NCI NIH HHS R01 CA195503NCI NIH HHS R01 CA200399NCI NIH HHS R01 CA216855NCI NIH HHS R43 CA221490NINDS NIH HHS R01 NS073611NINDS NIH HHS R01 NS096754NINDS NIH HHS R01 NS099460NINDS NIH HHS R01 NS110087NINDS NIH HHS R21 NS101400NINDS NIH HHS R21 NS106407Wellcome Trust
6 · The paper itself

Abstract

A subset of stem-like cells in glioblastoma (GBM; GSC) underlies tumor propagation, therapeutic resistance, and tumor recurrence. Immune evasion is critical for GSCs to carry out these functions. However, the molecular mechanisms employed by GSCs to escape antitumor immunity remain largely unknown. The reprogramming transcription factors Oct4 and Sox2 function as core multipotency factors and play an essential role in the formation and maintenance of GSCs, but the roles of these transcription factors in GSC immune escape have not been well explored. Here we examine how Oct4/Sox2 coexpression contributes to the immunosuppressive phenotype of GSCs. Combined transcription profiling and functional studies of Oct4/Sox2 coexpressing GSCs and differentiated GBM cells demonstrated that Oct4 and Sox2 cooperatively induce an immunosuppressive transcriptome consisting of multiple immunosuppressive checkpoints (i.e., PD-L1, CD70, A2aR, TDO) and dysregulation of cytokines and chemokines that are associated with an immunosuppressive tumor microenvironment. Mechanistically, induction and function of BRD/H3k27Ac-dependent immunosuppressive genes played a role in the immunosuppressive phenotype of GSCs. Pan-BET bromodomain inhibitors (e.g., JQ1) and shBRD4 constructs significantly inhibited the immunosuppressive transcriptome and immunosuppressive biological responses induced by Oct4/Sox2. Our findings identify targetable mechanisms by which tumor-propagating GSCs contribute to the immunosuppressive microenvironment in GBM. SIGNIFICANCE: This report identifies mechanisms by which the reprogramming transcription factors Oct4 and Sox2 function to drive the immunomodulatory transcriptome of GSCs and contribute to the immunosuppressive microenvironment in GBM.

Indexed as

Immune ToleranceAnimalsApoptosisBrain NeoplasmsBromodomain Containing ProteinsCD8-Positive T-LymphocytesCell Cycle ProteinsCell MovementFemaleGlioblastomaHumansJurkat CellsMiceMice, Inbred C57BLNeoplastic Stem CellsOctamer Transcription Factor-3BRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsOctamer Transcription Factor-3POU5F1 protein, humanPou5f1 protein, mouseSOX2 protein, humanSox2 protein, mouseSOXB1 Transcription FactorsTranscription Factors

Identifiers

PMID33574085
PMCPMC8137560
OpenAlexW3126439695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.